Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

Newly launched company, Verdiva Bio, is aiming to advance oral and injectable drugs for obesity, with it backed by an ...

The newly launched biotech is equipped with rights to a trio of weight loss medicines licensed from China-based Sciwind ...

Verdiva Bio Limited ("Verdiva" or "the Company") today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...

Stada has lined up a new independent chairman and board of directors in a key step for the private equity-backed German drug ...

The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...